| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Chronic Myeloid Leukemia |
From the Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy (SS, SC, AG, FC, GR, CB, SP, MR, PPP, FP, PG, GM, SL, NT, II, MB, GM); Department of Clinical and Biological Science, University of Turin, Orbassano, Italy (DC, GS).
Correspondence: Giovanni Martinelli, MD, Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", S. Orsola-Malpighi Hospital, Massarenti 9, 40138 Bologna, Italy. E-mail: gmarti-no{at}kaiser.alma.unibo.it
The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant forms of Bcr-Abl, including dasatinib (BMS-354825; Bristol-Myers Squibb). In order to assess which pre-existent or emerging kinase domain mutations are associated with decreased clinical efficacy of desatinib, we analyzed BCR-ABL kinase sequences before and during treatment in 21 Ph+ patients who failed to respond to or relapsed during dasatinib therapy. In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317.
Key words: chronic myeloid leukemia, acute lymphoblastic leukemia, imatinib, dasatinib, resistance, Bcr-Abl, mutations.
This article has been cited by other articles:
|
|
 |
|
  M. W. Deininger Nilotinib Clin. Cancer Res., July 1, 2008; 14(13): 4027 - 4031. [Full Text] [PDF]
|
|
|
|
 |
|
 T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib PNAS, April 8, 2008; 105(14): 5507 - 5512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Kenealy, C. B. Christenson, and C. B. Williams Current Therapies for Chronic Myeloid Leukemia Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Khorashad, D. Milojkovic, P. Mehta, M. Anand, S. Ghorashian, A. G. Reid, V. De Melo, A. Babb, H. de Lavallade, E. Olavarria, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib Blood, February 15, 2008; 111(4): 2378 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Soverini, I. Iacobucci, M. Baccarani, and G. Martinelli Targeted therapy and the T315I mutation in Philadelphia-positive leukemias Haematologica, April 1, 2007; 92(4): 437 - 439. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Branford Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice Hematology, January 1, 2007; 2007(1): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
